The abstract of this paper is like many others in that it switches between "high cholesterol" and "low-density lipoprotein (LDL)-cholesterol". Well, perhaps it all makes more sense in the full paper? (Though that is behind a paywall.) Still, the simple observation of an association is interesting and might help to pave the way to some understanding of the disease processes.
J Endocrinol Invest. 2018 Jun 19. doi: 10.1007/s40618-018-0915-z. [Epub ahead of print]
Relationship between serum cholesterol and Graves' orbitopathy (GO): a confirmatory study.
Lanzolla G1, Sabini E1,2, Profilo MA1, Mazzi B1, Sframeli A3, Rocchi R1, Menconi F1, Leo M1, Nardi M3, Vitti P1, Marcocci C1, Marinò M4.
1 Endocrinology Units, Department of Clinical and Experimental Medicine, University of Pisa and University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy.
2 Division of Immunology, Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, MD, USA.
3 Ophthalmopathy Unit I, Department of Surgical, Medical and Molecular Pathology, University of Pisa and University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy.
4 Endocrinology Units, Department of Clinical and Experimental Medicine, University of Pisa and University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy. firstname.lastname@example.org.
It has been suggested that high cholesterol represents a risk factor for Graves' orbitopathy (GO). In a recent cross-sectional study, a correlation between cholesterol and the presence of GO was found in patients with a Graves' disease (GD) of recent onset. To confirm this observation, we conducted a retrospective investigation in consecutive patients with GD. The primary outcome was the relationship between the presence of GO and low-density lipoprotein (LDL)-cholesterol.
The design entailed the inclusion of consecutive patients with a GD of recent onset, with or without GO, who came to our observation to receive radioiodine over a period of 6 months, and a stratification aimed at having two homogeneous group of patients in terms of thyroid function. A total of 86 patients fulfilled the inclusion and evaded the exclusion criteria. All patients underwent an ophthalmological assessment and serum lipids were measured.
Serum levels of LDL-cholesterol were significantly higher in patients with GO (135.3 ± 41.3 mg/dL) compared with those without GO (106.6 ± 23.9 mg/dL, P = 0.0007). In a similar manner, serum levels of total cholesterol were higher in patients with GO (211.6 ± 44.0 mg/dL) than in those without GO (176.0 ± 27.2 mg/dL, P = 0.0001). There was no relationship between GO severity and activity and cholesterol. There was no relationship between GO and high-density lipoprotein-cholesterol or triglycerides.
Our study confirms a relationship between the presence of GO and cholesterol in patients with GD of recent onset. Whether lowering of cholesterol ameliorates, GO remains to be established.
Cholesterol; Graves; Ophthalmopathy; Orbitopathy; Statins